A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-G

Inclusion Criteria

The subjects have to meet all of the following criteria to be eligible to enter the investigation:

• Signed Informed Consent Form
• Age >18
• Diagnose with FD or IB Rome III criteria
• Is able to complete the diary, use the device and to follow study procedures
• Dyspepsia inclusion criteria, functional dyspepsia according to Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders, one or more of the following:
• Bothersome postprandial fullness
• Early satiation
• Epigastric pain
• Epigastric burning
• No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms * Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
• IBS inclusion criteria, Irritable Bowel Syndrome* according to Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders
• Recurrent abdominal pain or discomfort** at least 3 days/month in the previous 3 months associated with two or more of the following:
• Improvement with defecation
• Onset associated with a change in frequency of stool
• Onset associated with a change in form (appearance) of stool
• Criterion fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis ** "Discomfort" means an uncomfortable sensation not described as pain.
• In pathophysiology research and clinical trials, a pain/discomfort frequency of at least 2 days a week during screening evaluation is recommended for subject eligibility.

Exclusion Criteria

Subjects meeting any of the following criteria will not be permitted to enter the investigation:

• Any positive endoscopic findings such as abnormal biopsy findings and/or any other abnormal finding judged by the Investigator
• Any positive findings after sigmoidoscopy or colonoscopy such as diverticulosis, inflammatory bowel disease or other abnormal finding judged by the Investigator.
• Vagotomy at any location
• Has a neck lesion (including lymphadenopathy), dysaesthesia, previous surgery or abnormal anatomy at the site gammaCore®-G treatment
• Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g. bruits or history of transient ischemic attack (TIA) or cerebral vascular accident CVA), congestive heart failure (CHF), known severe coronary artery disease or recent (5 years) myocardial infarction
• Has an abnormal baseline ECG (e.g. second and third degree heart block, atrial fibrillation, atrial flutter, recent history of ventricular tachycardia or ventricular fibrillation, or clinically significant premature ventricular contraction
• Has uncontrolled hypertension
• Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, gastric stimulator or cochlear implant
• Has a history of carotid endarterectomy or vascular neck surgery
• Has been implanted with metal cervical spine hardware or has a metallic implant near the GammaCore®-G stimulation site
• Has a recent (within 12 months) or repeated history of syncope
• Has a recent (within 12 months) or repeated history of seizures
• Has psychiatric or cognitive disorder and/or behavioural problems which in the opinion of the clinician may interfere with the study
• Is pregnant, nursing, thinking of becoming pregnant during the study period
• Is participating in any other therapeutic clinical investigation or has participated in a clinical trial within 30 days period prior to this study
• Is a relative of or an employee of the investigator or the clinical study site
• Used gammaCore®-G previously